Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atabecestat in Japanese Asymptomatic at Risk for Alzheimer Dementia
NCT02360657Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2015
- Primary completion
- Sep 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Levels of Amyloid (A)-beta1-40 in Cerebrospinal Fluid (CSF) at 4 weeks, Levels of A-beta1-40 in Plasma at 4 weeks and 6 more. Started Feb 2015; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02360657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360657.